胆管癌治療薬の世界市場2019-2023...市場調査レポートについてご紹介

【英文タイトル】Global Cholangiocarcinoma Therapeutics Market 2019-2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Intrahepatic cholangiocarcinoma – Market size and forecast 2018-2023
• Extrahepatic cholangiocarcinoma – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Sanofi
PART 14: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market
Exhibit 08: Global market
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Global cholangiocarcinoma therapeutics market pipeline
Exhibit 18: Global cholangiocarcinoma therapeutics market pipeline
Exhibit 19: Type – Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Intrahepatic cholangiocarcinoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Intrahepatic cholangiocarcinoma – Year-over-year growth 2019-2023 (%)
Exhibit 23: Extrahepatic cholangiocarcinoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Extrahepatic cholangiocarcinoma – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Bristol-Myers Squibb Company – Vendor overview
Exhibit 46: Bristol-Myers Squibb Company – Business segments
Exhibit 47: Bristol-Myers Squibb Company – Organizational developments
Exhibit 48: Bristol-Myers Squibb Company – Geographic focus
Exhibit 49: Bristol-Myers Squibb Company – Key offerings
Exhibit 50: Bristol-Myers Squibb Company – Key customers
Exhibit 51: Eli Lilly and Company – Vendor overview
Exhibit 52: Eli Lilly and Company – Business segments
Exhibit 53: Eli Lilly and Company – Organizational developments
Exhibit 54: Eli Lilly and Company – Geographic focus
Exhibit 55: Eli Lilly and Company – Segment focus
Exhibit 56: Eli Lilly and Company – Key offerings
Exhibit 57: Eli Lilly and Company – Key customers
Exhibit 58: F. Hoffmann-La Roche Ltd – Vendor overview
Exhibit 59: F. Hoffmann-La Roche Ltd – Business segments
Exhibit 60: F. Hoffmann-La Roche Ltd – Organizational developments
Exhibit 61: F. Hoffmann-La Roche Ltd – Geographic focus
Exhibit 62: F. Hoffmann-La Roche Ltd – Segment focus
Exhibit 63: F. Hoffmann-La Roche Ltd – Key offerings
Exhibit 64: F. Hoffmann-La Roche Ltd – Key customers
Exhibit 65: Pfizer Inc. – Vendor overview
Exhibit 66: Pfizer Inc. – Business segments
Exhibit 67: Pfizer Inc. – Organizational developments
Exhibit 68: Pfizer Inc. – Geographic focus
Exhibit 69: Pfizer Inc. – Segment focus
Exhibit 70: Pfizer Inc. – Key offerings
Exhibit 71: Pfizer Inc. – Key customers
Exhibit 72: Sanofi – Vendor overview
Exhibit 73: Sanofi – Business segments
Exhibit 74: Sanofi – Organizational developments
Exhibit 75: Sanofi – Geographic focus
Exhibit 76: Sanofi – Segment focus
Exhibit 77: Sanofi – Key offerings
Exhibit 78: Sanofi – Key customers
Exhibit 79: Validation techniques employed for market sizing


【レポート販売概要】

■ タイトル:胆管癌治療薬の世界市場2019-2023
■ 英文:Global Cholangiocarcinoma Therapeutics Market 2019-2023
■ 発行日:2019年2月23日
■ 調査会社:Technavio
■ 商品コード:IRTNTR30865
■ 調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。